PALI Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 10.38%, SMA50 0.31%, SMA200 39.7%). The stock’s 14-day RSI is 55.31 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.92% below its high and over 249.06% above its low. Average 10-day trading volume of 5.16 million shares is slightly above the 3-month average of 3.84 million, indicating heightened recent market interest.

Palisade Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.39. This means the shares are trading below this model’s fair value.

Palisade Bio, Inc. (NASDAQ:PALI) closed at $1.97 USD, losing -$0.08 (-3.90%) from the previous close of $2.05. The stock is currently mid-range between its 52-week high and low $0.53 and $2.86. With a market capitalization of about $341.95 million, Palisade Bio, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.51). Key stats such as the average daily volume over the past year has been around 3.91 million shares, in line with its 52-week average. Headquartered in Carlsbad, CA, Palisade Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO J. D. Finley, the company employs approximately 14 people and listed since March 30, 2007. Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier.

Palisade Bio, Inc. generated EPS of -$4.22 over the past year. Five-year average earnings growth is 77.35%. Wall Street analysts project EPS growth of 67.97% annually over the next five years. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at -$0.04. Next year's EPS is expected at $49.06. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $5.00. The high target offers 1169.04% upside. The low target suggests 153.81% downside. The mean target is $10.50. This offers 432.99% upside. Palisade Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 25.0%. The prior quarter beat by 100.0%. Over the last six quarters, Apple has recorded several small beats. These include -65.33% in March 24, 2025.

Palisade Bio, Inc. has 9.12 million shares outstanding. The public float is 8.62 million shares, elevated short interest at 4.68% of float. This equals 424.35 thousand shares. The short ratio is 0.08 days. Institutional investors hold 5.93% of the float. Insiders own 0.24%. JOHE KARL holds 826.30 thousand shares, Baltera Robert Jr. has 416.90 thousand shares and GARR RICHARD has 240.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 204.56 thousand shares across 4 transactions.

Palisade Bio, Inc. trades at a P/E ratio of -1.85, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.23 trading at moderately above to book value. The P/FCF stands at -27.5, also below market averages.

Our AI price prediction model suggests that Palisade Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.63%, with price expected at $2.14 by July 22, 2026, within a range of $1.97 to $2.29 3-Month Outlook: Projected rise of 77.66%, reaching $3.50 by October 06, 2026, with a range of $3.40 to $3.60. 1-Year Outlook: Projected gain of 178.17%, with price at $5.48 by July 08, 2027, within a range of $1.09 to $4.93.

Palisade Bio, Inc. (NASDAQ:PALI) shares are down -19.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Palisade Bio, Inc. trading at a premium to the broader market with a P/E of -1.85. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $18.95, suggesting 861.93% upside. Our AI forecast model points to short-term strength (8.63% over two weeks), a medium-term rise (77.66% over three months), and a longer-term gain (178.17% over one year), with expected trading ranges indicating moderate volatility.